This study was designed to evaluate the safety and performance of Metaforâ„¢ SES in real-world patients with coronary artery disease. This was retrospective, single-centre, post-marketing, observational study. The primary endpoint was the occurrence of major adverse cardiac event (MACE).
View Article and Find Full Text PDF